Using non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases

References

• Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429. doi:10.1093/eurheartj/ehq27820802247
   PubMed Web of Science ®Google Scholar
• What is atrial fibrillation? National institutes of health. Available from: https://www.nhlbi.nih.gov/health/health-topics/topics/af. Published 2014 Accessed 130, 2017.
   Google Scholar
• What are the signs and symptoms of atrial fibrillation? National institutes of health. Available from: https://www.nhlbi.nih.gov/health/health-topics/topics/af/signs. Published 2014 Accessed 130, 2017.
   Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–988.1866765
   PubMed Web of Science ®Google Scholar
• Tse HF, Wang YJ, Ahmed Ai-Abdullah M, et al. Stroke prevention in atrial fibrillation – an Asian stroke perspective. Heart Rhythm. 2013;10(7):1082–1088. doi:10.1016/j.hrthm.2013.03.01723501173
   PubMed Web of Science ®Google Scholar
• Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111(5):789–797. doi:10.1160/TH13-11-094824500243
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25(3):235–242. doi:10.1016/j.beha.2012.06.00722959540
   PubMed Web of Science ®Google Scholar
• What is deep vein thrombosis? National institutes of health. Available from: https://www.nhlbi.nih.gov/health/health-topics/topics/dvt/. Published 2011 Accessed 327, 2017.
   Google Scholar
• What is pulmonary embolism? National institutes of health. Available from: https://www.nhlbi.nih.gov/health/health-topics/topics/pe/. Published 2011 Accessed 327, 2017.
   Google Scholar
• Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363–2371.
   Google Scholar
• Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the health insurance review and assessment service database. J Thromb Haemost. 2011;9(1):85–91. doi:10.1111/j.1538-7836.2010.04108.x20942850
   PubMed Web of Science ®Google Scholar
• Hong J, Lee JH, Yhim HY, et al. Incidence of venous thromboembolism in Korea from 2009 to 2013. PLoS One. 2018;13(1):e0191897. doi:10.1371/journal.pone.019189729370290
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23):2071–2104. doi:10.1161/CIR.000000000000004024682348
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed). 2017;70(1):50. doi:10.1016/j.rec.2016.11.03328038729
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi:10.1016/j.chest.2015.11.02626867832
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–3069, 3069a-3069k. doi:10.1093/eurheartj/ehu283
   Web of Science ®Google Scholar
• Label information of COUMADIN. U.S. food and drug administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/009218s116lbl.pdf. Published 2016 Accessed 21, 2017.
   Google Scholar
• Label information of LOVENOX. U.S. food and drug administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020164s102lbl.pdf. Published 2013 Accessed 527, 2017.
   Google Scholar
• Label information of INNOHEP. U.S. food and drug administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Published 2010 Accessed 527, 2017.
   Google Scholar
• Label information of FRAGMIN. U.S. food and drug administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020287s069lbl.pdf. Published 2017 Accessed 527, 2017.
   Google Scholar
• Sinauridze EI, Panteleev MA, Ataullakhanov FI. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis. 2012;23(6):482–493. doi:10.1097/MBC.0b013e328355c9cb22732252
   PubMed Web of Science ®Google Scholar
• Label information of ARIXTRA. U.S. food and drug administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021345s032lbl.pdf. Published 2014 Accessed 527, 2017.
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa090556119717844
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875–1876. doi:10.1056/NEJMc100737821047252
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med. 2014;371(15):1464–1465. doi:10.1056/NEJMc140790825251519
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa100963821830957
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa110703921870978
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi:10.1056/NEJMoa131090724251359
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa090659819966341
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–772. doi:10.1161/CIRCULATIONAHA.113.00445024344086
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718. doi:10.1056/NEJMoa111369723425163
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. doi:10.1056/NEJMoa100790321128814
   PubMed Web of Science ®Google Scholar
• Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297. doi:10.1056/NEJMoa111357222449293
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. doi:10.1056/NEJMoa130250723808982
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. doi:10.1056/NEJMoa120754123216615
   PubMed Web of Science ®Google Scholar
• Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415. doi:10.1056/NEJMoa130663823991658
   PubMed Web of Science ®Google Scholar
• Cho IY, Choi KH, Sheen YY. How Does “Regulatory Practice” Create Discrepancies in Drug Label Information Between Asian and Western Countries? Different Label Information for Direct Oral Anticoagulants Approved in the United States, Europe, Korea, and Japan. Ther Innov Regul Sci. 2019;53(2):233–242.
   Google Scholar
• Macle L, Cairns J, Leblanc K, et al. 2016 focused update of the Canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol. 2016;32(10):1170–1185. doi:10.1016/j.cjca.2016.07.59127609430
   PubMed Web of Science ®Google Scholar
• JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010;74(11):2479–2500.20962419
   PubMed Web of Science ®Google Scholar
• Label information of PRADAXA. U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf. Published 2015 Accessed 28, 2017.
   Google Scholar
• PRADAXA: EPAR-Product Information. European medicines agency. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Published 2017 Accessed 28, 2017.
   Google Scholar
• Label information of Xarelto. U.S. food and drug administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022406s019s020lbl.pdf. Published 2016 Accessed 28, 2017.
   Google Scholar
• XARELTO: EPAR-Product Information. European medicines agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf. Published 2016 Accessed 28, 2017.
   Google Scholar
• Label information of ELIQUIS. U.S. Food And Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202155s012lbl.pdf. Published 2016 Accessed 28, 2017.
   Google Scholar
• Eliquis : EPAR – product information European medicines agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Published 2016 Accessed 28, 2017.
   Google Scholar
• Label information of SAVAYSA. U.S. food and drug administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206316s004lbl.pdf. Published 2016 Accessed 28, 2017.
   Google Scholar
• Lixiana : EPAR – Product Information European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf. Published 2016 Accessed 28, 2017.
   Google Scholar
• Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 2014;124(7):1020–1028. doi:10.1182/blood-2014-03-56305624923298
   PubMed Web of Science ®Google Scholar
• Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11(4):756–760. doi:10.1111/jth.2013.11.issue-4
   Google Scholar
• Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520. doi:10.1056/NEJMoa150200026095746
   PubMed Web of Science ®Google Scholar
• ANDEXXA: Summary Basis for Regulatory Action. U.S. food and drug administration. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm610006.pdf. Published 2018 Accessed 66, 2018.
   Google Scholar
• Edoxaban: CHMP assessment report. European medicines agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002629/WC500189047.pdf. Published 2015 Accessed 45, 2017.
   Google Scholar
• New drug approval report of LIXIANA. Korea ministry of food and drug safety. Available from: http://www.mfds.go.kr/index.do?x=0&searchkey=product_nm&mid=1176&searchword=릭시아나&cd=191&y=0&pageNo=1&seq=24202&cmd=v. Published 2016 Accessed 45, 2017.
   Google Scholar
• Approved label of pradaxa in Korea – Korean Ministry of Food and Drug Administration. Available from: http://www.health.kr/images/insert_pdf/IN_2011022100001_01.pdf. Published 2017 Accessed 721, 2017.
   Google Scholar
• Approved label of pradaxa in Japan pharmaceuticals and medical devices agency. Available from: http://www.info.pmda.go.jp/go/pack/3339001M1024_1_11/. Published 2016 Accessed 721, 2017.
   Google Scholar
• Summary review of PRADAXA. U.S. food and drug administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000SumR.pdf. Published 2010 Accessed 212, 2017.
   Google Scholar
• Beasley BN, Unger EF, Temple R. Anticoagulant options – why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–1790. doi:10.1056/NEJMp110305021488759
   PubMed Web of Science ®Google Scholar
• Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014;111(5):933–942. doi:10.1160/TH13-09-073424326736
   PubMed Web of Science ®Google Scholar
• Chan NC, Coppens M, Hirsh J, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost. 2015;13(3):353–359. doi:10.1111/jth.1282325523236
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164. doi:10.1161/CIRCULATIONAHA.114.01206125359164
   PubMed Web of Science ®Google Scholar
• Hernandez I. Time to reconsider dabigatran 110 mg in the USA. Am J Cardiovasc Drugs. 2015;15(5):307–309. doi:10.1007/s40256-015-0137-026068887
   PubMed Web of Science ®Google Scholar
• Lee KH, Park HW, Lee N, et al. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation. Europace. 2017;19(suppl_4):iv1–iv9. doi:10.1093/europace/eux24729220421
   PubMed Web of Science ®Google Scholar
• Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke. 2016;47(2):441–449. doi:10.1161/STROKEAHA.115.01147626732563
   PubMed Web of Science ®Google Scholar
• Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44(7):1891–1896. doi:10.1161/STROKEAHA.113.00099023743976
   PubMed Web of Science ®Google Scholar
• Cho MS, Yun JE, Park JJ, et al. Outcomes after use of standard- and low-dose non-vitamin k oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2019;50:110–118. Strokeaha118023093.
   Web of Science ®Google Scholar
• Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Optimal rivaroxaban dose in Asian patients with atrial fibrillation and normal or mildly impaired renal function. Stroke. 2019;50(5):1140–1148. doi:10.1161/STROKEAHA.118.02421030913984
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–2604. doi:10.1016/j.jacc.2016.09.96627978942
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J. 2012;76(9):2104–2111.22664783
   PubMed Web of Science ®Google Scholar
• Chan YH, See LC, Tu HT, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7:8. doi:10.1161/JAHA.118.008528
   Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-Vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790. doi:10.1016/j.jacc.2017.03.60028595692
   PubMed Web of Science ®Google Scholar
• Risk assessment and risk mitigation review. U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s000RiskR.pdf. Published 2015 Accessed 216, 2017.
   Google Scholar
• Summary of the risk management plan (RMP) for Lixiana (edoxaban). European medicines agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Risk-management-plan_summary/human/002629/WC500186050.pdf. Published 2015 Accessed 227, 2017.
   Google Scholar
• Lee SR, Choi EK, Han KD, et al. Non-vitamin K antagonist oral anticoagulants in Asian patients with supranormal renal function. Stroke. 2019;50(6):1480–1489. doi:10.1161/STROKEAHA.118.02426431084339
   PubMed Web of Science ®Google Scholar
• Lee KH, Joung B, Lee S-R, et al. 2018 KHRS expert consensus recommendation for oral anticoagulants choice and appropriate doses: specific situation and high risk patients. Korean J Intern Med. 2018;93(2):110–132. doi:10.3904/kjm.2018.93.2.110
   Google Scholar
• Approved label of lixiana in Japan pharmaceuticals and medical devices agency. Available from: http://www.info.pmda.go.jp/go/pack/3339002F1020_1_08/. Published 2016 Accessed 721, 2017.
   Google Scholar
• Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology working group on thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–3179. doi:10.1093/eurheartj/ehu29825154388
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. doi:10.1056/NEJMoa161159427959713
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524. doi:10.1056/NEJMoa170845428844193
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524. doi:10.1056/NEJMoa181708330883055
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–1115. doi:10.1016/S0140-6736(12)62177-123415013
   PubMed Web of Science ®Google Scholar
• Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127(5):634–640. doi:10.1161/CIRCULATIONAHA.112.11538623271794
   PubMed Web of Science ®Google Scholar
• Chen CH, Chen MC, Gibbs H, et al. Antithrombotic treatment for stroke prevention in atrial fibrillation: the Asian agenda. Int J Cardiol. 2015;191:244–253. doi:10.1016/j.ijcard.2015.03.36925978611
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019 Cir0000000000000665. doi:10.1161/CIR.0000000000000665
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138(5):527–536. doi:10.1161/CIRCULATIONAHA.118.03472230571525
   PubMed Web of Science ®Google Scholar
• Lip GYH, Collet JP, Haude M, Huber K. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: a summary of the joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology working group on thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Eur Heart J. 2018;39(31):2847–2850. doi:10.1093/eurheartj/ehy39630137444
   PubMed Web of Science ®Google Scholar
• Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ENTRUST-AF-PCI, NCT02866175). Available from: ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT02866175?term=NCT02866175&rank=1. Accessed 428, 2019.
   Google Scholar
• Kalra PA, Burlacu A, Ferro CJ, Covic A. Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease? Curr Opin Nephrol Hypertens. 2018;27(6):420–425. doi:10.1097/MNH.000000000000044330020140
   PubMed Web of Science ®Google Scholar
• Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant. 2012;27(10):3816–3822. doi:10.1093/ndt/gfs41623114904
   PubMed Web of Science ®Google Scholar
• Heine GH, Brandenburg V, Schirmer SH. Oral anticoagulation in chronic kidney disease and atrial fibrillation. Dtsch Arztebl Int. 2018;115(17):287–294. doi:10.3238/arztebl.2018.028729789105
   PubMed Web of Science ®Google Scholar
• Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Eur Heart J. 2018;39(24):2314–2325. doi:10.1093/eurheartj/ehy06029522134
   PubMed Web of Science ®Google Scholar
• Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–1222. doi:10.1056/NEJMoa170051828316279
   PubMed Web of Science ®Google Scholar
• Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425–1434. doi:10.1056/NEJMoa03502912601075
   PubMed Web of Science ®Google Scholar
• Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018;16(7):1288–1295. doi:10.1111/jth.1415629772108
   PubMed Web of Science ®Google Scholar
• Yamada N, Hirayama A, Maeda H, et al. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program. Thromb J. 2015;13:2. doi:10.1186/s12959-015-0035-325717286
   PubMed Web of Science ®Google Scholar
• JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75(5):1258–1281.21441695
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–815.10737280
   PubMed Web of Science ®Google Scholar
• Halamkova J, Penka M. [Current recommendations for the prevention and treatment of venous thromboembolism in cancer patients]. Klin Onkol. 2017;30(2):100–105. doi:10.14735/amko201710028397505
   PubMedGoogle Scholar
• Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014;134(6):1214–1219. doi:10.1016/j.thromres.2014.09.03925457583
   PubMed Web of Science ®Google Scholar
• ASH 2018: Apixaban for the Treatment of Cancer-Associated VTE. The ASCO post. Available from: https://www.ascopost.com/News/59535. Published 2018 Accessed 530, 2019.
   Google Scholar
• McBane RD, Wysokinski WE, Le-Rademacher J, et al. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. Blood. 2018;132(Suppl 1):421.  doi: https://doi.org/10.1182/blood-2018-99-118808
   Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624.29231094
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023.29746227
   PubMed Web of Science ®Google Scholar
• Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158–163. doi:10.1016/j.thromres.2018.02.14429506866
   PubMed Web of Science ®Google Scholar
• Kim S-A, Yhim H-Y, Bang S-M. Current management of cancer-associated venous thromboembolism: focus on direct oral anticoagulants. J Korean Med Sci. 2019;34:6.
   Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656. doi:10.1200/JCO.2014.59.735125605844
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12:Cd008500. doi:10.1002/14651858.CD003091.pub427906452
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719. doi:10.1056/NEJMoa181446830511879
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. doi:10.1056/NEJMoa181463030786186
   PubMed Web of Science ®Google Scholar
• Potpara TS, Lane DA, Lip GY. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015;17(4):507–508. doi:10.1093/europace/euv04125833879
   PubMed Web of Science ®Google Scholar
• Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence. 2010;4:51–60.20361065
   PubMed Web of Science ®Google Scholar
• Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost. 2013;11(2):390–394. doi:10.1111/jth.1208623206117
   PubMed Web of Science ®Google Scholar
• Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419–434. doi:10.2147/PPA.S4464623737662
   PubMed Web of Science ®Google Scholar
• Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29(8):675–690. doi:10.1007/s12325-012-0040-x22898791
   PubMed Web of Science ®Google Scholar
• Laliberte F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6(3):213–224. doi:10.1007/s40271-013-0020-523857628
   PubMedGoogle Scholar
• Ikeda T, Yasaka M, Kida M, Imura M. A survey of reasons for continuing warfarin therapy in the era of direct oral anticoagulants in Japanese patients with atrial fibrillation: the SELECT study. Patient Prefer Adherence. 2018;12:135–143. doi:10.2147/PPA.S15258429398909
   PubMed Web of Science ®Google Scholar
• GoodRx. Available from: https://www.goodrx.com/. Accessed 1210, 2018.
   Google Scholar
• British national formulary March - September 2017. Available from: https://vnras.com/wp-content/uploads/2017/06/BNF-73-2017.pdf. Accessed 1210, 2018.
   Google Scholar
• KIMS. Available from: http://www.kimsonline.co.kr/. Accessed 1210, 2018.
   Google Scholar
• yakka-search. Available from: https://yakka-search.com/. Accessed 16, 2019.
   Google Scholar
• Bang OY, Hong KS, Heo JH, et al. New oral anticoagulants may be particularly useful for Asian stroke patients. J Stroke. 2014;16(2):73–80. doi:10.5853/jos.2014.16.2.7324949312
   PubMed Web of Science ®Google Scholar
• Kim IY. Analysis of Anticoagulants Drug Expenditure and Usage: Focused on Stroke Prevention in Non-valvular Atrial Fibrillation in Korea. Seoul: The Graduate School, Sungkyunkwan University; 2018.
   Google Scholar
• Kumana CR, Cheung BM, Siu DC, Tse HF, Lauder IJ. Non-vitamin K oral anticoagulants versus warfarin for patients with atrial fibrillation: absolute benefit and harm assessments yield novel insights. Cardiovasc Ther. 2016;34(2):100–106. doi:10.1111/1755-5922.1217326727005
   PubMed Web of Science ®Google Scholar
• Kyung-Ah Lee M, Han-Ra Park M. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation patients in Korea. J Health Tech Assess. 2014;2(2):105–113.
   Google Scholar
• Kim JS, Oh YH, Kim JD. Cost-effectiveness of dabigatran etexilate versus warfarin for the prevention of stroke and systemic embolism in Korea patients with non-valvular atrial fibrillation. J Health Technol Assess. 2014;2(2):124–129.
   Google Scholar
• Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Korean Circ J. 2019;49(3):252–263.30468041
   PubMed Web of Science ®Google Scholar
• Ko Y-J, Kim S, Park K, et al. Impact of the health insurance coverage policy on oral anticoagulant prescription among patients with atrial fibrillation in Korea from 2014 to 2016. J Korean Med Sci. 2018;33:23. doi:10.3346/jkms.2018.33.e101
   Web of Science ®Google Scholar